Table 2 Clinicopathological manifestations between patients who received PTR and those who did not before and after PSM
Variables | Original cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|
PTR (n = 32) | No PTR (n = 36) | P | PTR (n = 26) | No PTR (n = 26) | P | |
Gender, n (%) | 0.931 | 1 | ||||
Male | 19 (59.4%) | 21 (58.3%) | 14 (53.8%) | 14 (53.8%) | ||
Female | 13 (40.6%) | 15 (41.7%) | 12 (46.2%) | 12 (46.2%) | ||
Age (yr, mean ± SD) | 58.5 ± 9.8 | 57.3 ± 14.5 | 0.696 | 57.8 ± 8.7 | 57.5 ± 14.7 | 0.798 |
ECOG score | 0.092 | 1 | ||||
0–1 | 29 (90.6%) | 27 (75%) | 23 (88.5%) | 23 (88.5%) | ||
≥ 2 | 3 (9.4%) | 9 (25%) | 3 (11.5%) | 3 (11.5%) | ||
Primary tumor site, n (%) | 0.916 | 0.760 | ||||
Rectum | 22 (68.8%) | 25 (69.4%) | 19 (73.1%) | 18 (69.2%) | ||
Colon | 3 (9.4%) | 3 (8.3%) | 7 (26.9%) | 8 (30.8%) | ||
Grade | 0.676 | 0.506 | ||||
G1 | 3 (9.4%) | 2 (5.6%) | 3 (11.5%) | 2 (7.7%) | ||
G2 | 8 (25%) | 7 (19.4%) | 8 (30.8%) | 5 (19.2%) | ||
G3 | 21 (65.6%) | 27 (75%) | 15 (57.7%) | 19 (73.1%) | ||
Differentiation | 0.102 | 0.262 | ||||
NET | 16 (50%) | 11 (30.6%) | 13 (50%) | 9 (34.6%) | ||
NEC | 16 (50%) | 25 (69.4%) | 13 (50%) | 17 (65.4%) | ||
Clinical T stage, n (%) | 0.562 | 0.638 | ||||
T1, T2 | 4 (12.5%) | 2 (5.6%) | 3 (11.5%) | 2 (7.7%) | ||
T3, T4 | 28 (87.5%) | 34 (94.4%) | 23 (88.5%) | 24 (92.3%) | ||
Clinical N stage, n (%) | 0.340 | 1 | ||||
N0 | 2 (6.3%) | 6 (16.7%) | 1 (3.8%) | 1 (3.8%) | ||
N1 | 30 (93.8%) | 30 (83.3%) | 25 (96.2%) | 25 (96.2%) | ||
Site of metastasis, n (%) | 0.457 | 0.781 | ||||
Single-organ | 18 (56.3%) | 17 (47.2%) | 13 (50%) | 12 (46.2%) | ||
Multiple-organ | 14 (43.8%) | 19 (52.8%) | 13 (50%) | 14 (53.8%) | ||
Cycles of chemotherapy [median (range)] | 5 (0, 42) | 5 (0, 22) | 0.848 | 5 (0, 33) | 6 (0, 22) | 0.392 |